BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.95 USD
-0.19 (-2.33%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $7.96 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BCRX 7.95 -0.19(-2.33%)
Will BCRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCRX
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
BCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts
Other News for BCRX
BioCryst Pharmaceuticals Q2 2025 Earnings Preview
Earnings Outlook For BioCryst Pharma
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO
BioCryst Pharmaceuticals Announces CEO Transition | BCRX stock news
BioCryst (BCRX) Announces Leadership Transition Plan